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Plasma Renin Activity and Aldosterone Concentrations in
Hypertensive Cats with and without Azotemia and in Response to
Treatment with Amlodipine Besylate
R.E. Jepson, H.M. Syme, and J. Elliott
Background: Role of renin-angiotensin aldosterone system (RAAS) in feline systemic hypertension is poorly under-
stood.
Objectives: Examine plasma renin activity (PRA) and plasma aldosterone concentrations (PAC) in normotensive and
hypertensive cats with variable renal function and in response to antihypertensive therapy.
Animals: One hundred and ninety-six cats >9 years from first opinion practice.
Methods: PRA, PAC, and aldosterone-to-renin ratio (ARR) were evaluated in cats recruited prospectively and grouped
according to systolic blood pressure (SBP) and renal function (nonazotemic normotensive [Non-Azo-NT], nonazotemic
hypertensive [Non-Azo-HT], azotemic normotensive [Azo-NT], azotemic hypertensive [Azo-HT]). Changes in PRA and
PAC were evaluated with antihypertensive therapy (amlodipine besylate).
Results: Plasma renin activity (ng/mL/h; P = .0013), PAC (pg/mL; P < .001), and ARR (P = 0.0062) differed signifi-
cantly among groups. PRA (ng/mL/h) was significantly lower in hypertensive (Non-Azo-HT; n = 25, median 0.22 [25th
percentile 0.09, 75th percentile 0.39], Azo-HT; n = 44, 0.33 [0.15, 0.48]) compared with Non-Azo-NT cats (n = 57, 0.52
[0.28, 1.02]). Azo-HT cats had significantly higher PAC (n = 22, 149.8 [103.1, 228.7]) than normotensive cats (Non-Azo-
NT; n = 26, 45.4 [19.6, 65.0], Azo-NT; n = 18, 84.1 [38.6, 137.8]). ARR was significantly higher in Azo-HT (n = 20, 503.8
[298.8, 1511]) than Azo-NT cats (n = 16, 97.8 [77.0, 496.4]). Significant increase in PRA was documented with antihyper-
tensive therapy (pretreatment [n = 20] 0.32 [0.15–0.46], posttreatment 0.54 [0.28, 1.51]), but PAC did not change.
Conclusions and Clinical Importance: Hypertensive cats demonstrate significantly increased PAC with decreased PRA.
PRA significantly increases with antihypertensive therapy. Additional work is required to determine the role of plasma
aldosterone concentration in the pathogenesis of hypertension and whether this relates to autonomous production or acti-
vation of RAAS without demonstrable increase in PRA.
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Systemic hypertension in cats has been widelydescribed in the veterinary literature, but its patho-
genesis remains poorly understood.1 The kidneys are
integral to sodium balance and fluid volume regula-
tion. Altered renal function and pressure natriuresis
play potential roles in the development of systemic
hypertension. Stimulation of the renin-angiotensin-
aldosterone system (RAAS) is often considered as a
link among renal disease, sodium retention, volume
expansion, peripheral vascular resistance, and systemic
hypertension. In recent years, the importance of tissue-
specific RAAS, which operates independently from
systemic RAAS, has also been realized.2
To date, only a limited number of studies have
examined components of the RAAS in feline CKD
and systemic hypertension.3,4 In such studies, results
have been contradictory but have suggested increased
plasma aldosterone concentrations (PAC; pg/mL) but
variable plasma renin activity (PRA; ng/mL/h). How-
ever, these studies have been limited by small group
sizes, prior introduction of low sodium renal diets, and
lack of appropriate age-matched control groups.
Previous epidemiologic studies have documented
that cats with systemic hypertension have lower
plasma potassium concentration than normotensive
cats with comparable renal function.1,5 Relative or
absolute hyperaldosteronism could be a possible cause.
Hypertensive cats with naturally occurring CKD and
experimentally induced renal insufficiency respond
poorly to treatment with angiotensin-converting
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enzyme inhibitors (ACEi).4,6–8 The study by Steele and
colleagues evaluated the effect of ACEi (benazepril or
enalapril) therapy in cats with systemic hypertension
and CKD. They documented no change in systolic
blood pressure (SBP) and in concordance with this
finding, no significant change in PRA or PAC poten-
tially argues against a role for RAAS in the genesis of
systemic hypertension in the cat.9 However, alternative
explanations for inadequate antihypertensive response
to ACEi therapy in this study could be inadequate
dosage or poor bioavailability of the drugs studied.
Approximately 20% of cats diagnosed with systemic
hypertension are nonazotemic and do not have an
identifiable cause for their hypertension.10 These cats
demonstrate variable urine-concentrating ability, and
therefore mild CKD that has not resulted in azotemia
could be contributing to the development of systemic
hypertension.11 PRA and PAC have not been explored
previously in this group of cats. Amlodipine besylate,
a dihydropyridine calcium channel antagonist, has
been established as the first-line antihypertensive agent
for cats.10,12 The effect of this medication on PRA and
PAC in hypertensive cats has not previously been
investigated.
The aims of this study were to perform a cross-sec-
tional analysis of PRA, PAC after solvent extraction
from feline plasma and resuspension in human matrix,
and aldosterone-to-renin ratios (ARR) in cats with
variable renal function and in the pathogenesis of sys-
temic hypertension. An additional aim was to evaluate
the effect of the first-line antihypertensive agent,
amlodipine besylate, on PAC and PRA. Based on the
previously identified finding of significantly lower
plasma potassium concentrations in cats with systemic
hypertension, it was hypothesized that nonazotemic
and azotemic cats with systemic hypertension would
have significantly increased PAC that was driven by
increased PRA.
Materials and Methods
Case Selection and Sample Collection
Cats (>9 years) were recruited to the study between 1999 and
2011 from 2 first opinion practices in central London (People’s
Dispensary for Sick Animals, Bow and Beaumont Sainsbury
Animal Hospital, Camden). Cats included in this study have been
included in previous studies published by the authors, but PRA
and PAC data for these cats have not been reported previously.
At recruitment, a full history was obtained and physical examina-
tion performed. SBP was assessed using the Doppler techniquea
and indirect fundic examinations performed as previous
described.11
The collection and storage of blood samples was performed
with owner consent and the protocols adhered to within this
study had been approved by the Ethics and Welfare Committee
at the Royal Veterinary College. Blood samples were obtained by
jugular venipuncture and collected into lithium heparin and
EDTA. Samples were held on ice (4°C) for a maximum of
6 hours before centrifugationb and separation. Heparinized and
EDTA plasma samples were subsequently aliquoted and frozen
at 80°C until required for assessment of PRA and PAC, respec-
tively. Plasma biochemistry (heparin plasma) was performed at
an external commercial laboratory.c Total serum thyroxine con-
centration was assessed in all cats in which the history (eg, poly-
phagia, weight loss), physical examination findings
(eg, tachycardia, arrhythmia, poor body condition, palpable goi-
ter), or serum biochemical findings (increased alanine transferase
or alkaline phosphatase activities) raised concern for hyperthy-
roidism. Any cat diagnosed with hyperthyroidism (total
T4 > 55 nmol/L) or with a previous diagnosis of hyperthyroidism
was excluded from the study. In all cases in which the urinary
bladder was palpable, a urine sample was collected by cystocente-
sis. Urine sample handling, urinalysis, storage, and assessment of
urine protein-to-creatinine measurements (UP:C) were performed
as previously described.11 Urine culture was performed when
there was microscopic evidence of bacteriuria or pyuria or where
clinical signs (stranguria) were compatible with the presence of a
urinary tract infection.
Cats entered in the cross-sectional analysis were classified
according to their plasma biochemical profile and SBP. The
International Renal Interest Society (IRIS) provides a staging
system, based on plasma creatinine concentration, for the classi-
fication of cats diagnosed with CKD, where IRIS stage 1
(plasma creatinine concentration <1.6 mg/dL) and early IRIS
stage 2 (plasma creatinine concentration 1.6–2.8 mg/dL) reflect
cats with nonazotemic CKD. In this study, cats were diagnosed
with azotemic IRIS stage 2 CKD or greater on the basis of his-
tory (eg, polyuria, polydipsia), physical examination findings
(renal palpation), the presence of azotemia (plasma creatinine
concentration >2 mg/dL [177 lmol/L]), which reflected the
upper limit of the laboratory reference interval and, where possi-
ble, inappropriate urine-concentrating ability (USG <1.035).
Cats diagnosed with azotemic CKD were subsequently enrolled
into a renal care program allowing long-term monitoring of
their CKD. This ensured that persistence of azotemia was docu-
mented in all cats diagnosed with IRIS stage 2 or greater CKD,
on at least 2 occasions, a minimum of 2 weeks apart, and that
where urine samples were not available for assessment of USG
on the initial visit, measurements were available on subsequent
visits.
Systemic hypertension was diagnosed on the basis of SBP
>170 mmHg on at least 2 occasions 7–14 days apart or on a
single occasion if in association with clinical manifestations of
systemic hypertension, most often hypertensive choroidopathy or
retinopathy. All cats diagnosed with systemic hypertension were
treated with amlodipine besylated (0.625 mg/cat PO q24 h). Own-
ers of cats were offered a re-examination appointment 7–14 days
after initiating antihypertensive therapy to document efficacy of
treatment, with a target SBP <160 mmHg. In those cats in which
response to treatment was inadequate, the dose was increased to
1.25 mg/cat PO q24 h. Cats diagnosed with CKD could therefore
be classified according to their BP status: azotemic normotensive
(Azo-NT) and azotemic hypertensive (Azo-HT).
Cats were considered nonazotemic normotensive (Non-
Azo-NT) if they were deemed healthy by their owners and the
clinician responsible for the case, no abnormalities were identified
on physical examination, they were documented to be nonazo-
temic on plasma biochemical profile, and SBP <160 mmHg was
recorded. These cats did not have a diagnosis of CKD, although
no requirement was made for USG. An additional group of cats
was nonazotemic on the basis of a plasma biochemical profile,
but these cats were documented to be persistently hypertensive
warranting antihypertensive medication in each case. No require-
ment was made for USG. The presence of hypertension in these
cats suggests impaired renal response to hypertension and
therefore these cats were considered to have IRIS stage I and
early-stage 2 CKD. As such, this group of cats is referred to as
nonazotemic hypertensive (Non-Azo-HT) rather than idiopathic
hypertensive.
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Clinicopathologic variables, PRA, PAC, and ARR were
compared among groups based on SBP and renal function
(Non-Azo-NT, Non-Azo-HT, Azo-NT, Azo-HT). The ARR was
calculated by dividing the PAC by PRA. To provide groups of
normotensive and hypertensive cats that were matched according
to renal status, cats with IRIS stage 4 CKD (plasma creatinine
concentration >5 mg/dL) were excluded from the Azo-NT
group.1 Storage time from sample date to date of PRA and PAC
assay was calculated and compared among groups.
An additional cross-sectional analysis was performed to evalu-
ate the effect of renal function on PRA and PAC. Cats were clas-
sified according to their plasma creatinine concentration: Group
1 (plasma creatinine concentration <2.0 mg/dL), Group 2
(plasma creatinine concentration 2.0–2.8 mg/dL), and Group 3
(plasma creatinine concentration ≥2.9 mg/dL). Group 2 reflects
cats classified with azotemic IRIS stage 2 CKD and Group 3 cats
classified as IRIS stage 3 or 4 CKD. However, Group 1 poten-
tially contains a combination of cats both with and without a
diagnosis of nonazotemic CKD. All 3 groups contain both
normotensive and hypertensive cats.
Exclusion criteria for cats entered into both cross-sectional
analyses included concurrent medical conditions other than
CKD, systemic hypertension, or both, recent IV fluid therapy,
recent administration of medications other than antibiotic ther-
apy or routine endo- or ectoparasiticides, potassium supplemen-
tation, use of a low protein and low phosphorous (renal) diet, or
antihypertensive medications at the time of sampling. Every
attempt was made to exclude cats with evidence of prerenal azo-
temia based on both clinical and biochemical information includ-
ing USG whenever available.
In a smaller number of cats diagnosed with systemic hyperten-
sion (azotemic or nonazotemic), PRA and PAC were evaluated
once target BP (<160 mmHg) had been achieved. In all cases,
posttreatment samples were obtained within 3 months of starting
antihypertensive therapy.
Measurement of Plasma Renin Activity
PRA was measured in EDTA plasma using a commercially
available kit.e The assay involves an initial incubation phase to
generate angiotensin 1 (Ang-1) followed by quantitation of Ang-
1 by radioimmunoassay (RIA). The assay was performed in
accordance with the manufacturer’s instructions except that reac-
tion volumes were halved in the Ang-1 generation phase to halve
the volume of EDTA plasma required. Given this methodological
variation, inter- and intra-assay variability was assessed. EDTA
samples from multiple cats were pooled to provide plasma with
low and high PRA. Dilutional parallelism was assessed for the
RIA component of this assay.
Preliminary assessment of cryoactivation of renin was
assessed by comparing PRA of feline plasma after standard
handling (held on ice; 4°C) or maintaining samples at room
temperature (21°C) until analysis (6 hours). PRA was also com-
pared when measured immediately or after 40 days frozen at
80°C. PRA from normal healthy cats >9 years was used to
generate a reference interval. Whenever PRA was undetectable,
samples were assigned the arbitrary value of 0.05 ng/mL/h,
which was determined to be the lower limit of quantitation of
the assay.
Measurement of Solvent-Extracted Aldosterone
Concentration
Aldosterone was measured using a commercially available
RIAf performed in accordance with the manufacturer’s recom-
mendations and which has previously been validated for use with
heparinized feline plasma samples.4,13,14 Before RIA, aldosterone
was extracted from feline plasma and resuspended in human
matrix.15
For the extraction process, 10 mL dicloromethaneg was added
to 0.5 ml EDTA plasma and 5000 disintegrations per minute
[3H]-aldosterone (50 pg)h and shaken vigorously for 20 minutes.
The aqueous phase was discarded and the extract was evaporated
to dryness at 40°C under a constant stream of room air. Then,
the residue was dissolved in 0.5 mL human matrix (zero human
standard from kit). To evaluate recovery from the extraction pro-
cess, disintegrations per minute were compared when 50 lL of
extracted sample or 50 lL of [3H]-aldosteronek was added to
4.5 mL of scintillation fluidi and counted in a scintillation coun-
ter.j An adjustment was made to the RIA measurement of aldo-
sterone to correct for both the efficiency of the extraction process
and the [3H]-aldosteronek added to the samples.
A reference interval was generated from normal healthy geriat-
ric cats using this technique. Intra- and interassay variability was
assessed using pooled heparinized feline plasma to give low and
high PAC. Dilutional parallelism was assessed after extraction of
aldosterone.
Statistical Analysis
Computerized statistical softwarek,l was used for all statistical
analyses. Probabilities <.05 were considered significant. Through-
out the study, data are presented as median [25th, 75th percen-
tile]. Inter- and intra-assay variability were assessed by
calculation of coefficient of variance (CV). Upper limit of refer-
ence intervals for PRA, extracted PAC, and ARR were calcu-
lated from the group of normal geriatric cats as mean + 2SD.
The influence of sample handling on PRA was assessed with a
Wilcoxon signed rank test.
Data for the cross-sectional analyses were assessed for nor-
mality using the Kolmogorov-Smirnov test. For data approach-
ing normality, significant differences among groups were
assessed using a one-way ANOVA with Bonferroni’s multiple
comparison posthoc analysis. For data that were not normally
distributed, the nonparametric Kruskall-Wallis test with Dunn’s
multiple comparison posthoc test was used. PRA, extracted
PAC, and ARR were not considered normally distributed
because of some samples being below the limit of detection
(PRA) and the presence of outliers. A Spearman’s rank correla-
tion was used to assess for any relationship between plasma
potassium concentration and extracted aldosterone concentration
either within the group of cats as a whole or more specifically
within those nonazotemic cats that were diagnosed with systemic
hypertension.
For paired data pre- and postamlodipine besylate therapy, a
Kolmogorov-Smirnov test was used to establish whether the
differences between pre- and posttreatment analyte values were
normally distributed. If differences were normally distributed, the
data were analysed using a paired student t-test. If differences
were not normally distributed, the Wilcoxon signed rank test was
used.
Results
One hundred and ninety-six cats were included in the
study, of which 105 (53.6%) were female neutered, 85
(43.4%) male neutered, 3 (1.5%) were intact males, and
3 (1.5%) intact females. The median age of cats
recruited to the study was 14.0 [25th percentile 11.6,
75th percentile 16.0] years. The majority of cats were
domestic shorthair (n = 154, 78.5%) or longhair
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(n = 15, 7.7%), with other breeds represented including
Persian (n = 13), British Shorthair (n = 4), Burmese
(n = 4), Siamese (n = 2), and 1 each of Birman, Chin-
chilla, Devon Rex and Bengal. One cat, which was
nonazotemic and hypertensive, was documented to
have hyperaldosteronism attributable to persistent
hypokalemia, the presence of an adrenal mass on ultra-
sound examination, and marked hyperaldosteronism
(617 pg/mL). This cat was excluded from further data
analysis. Of the remaining cats, 39.5% (n = 77) were
hypertensive with 76.6% of hypertensive cats demon-
strating evidence of hypertensive retinopathy, choroid-
opathy, or both.
Measurement of Plasma Renin Activity
The mean measured PRA for pooled feline plasma
were 0.50 ng/mL/h and 7.50 ng/mL/h. Intra-assay
coefficients of variation (n = 6) for the low and high
samples were 16.8% and 12.6%, respectively. Inter-
assay CVs (n = 5) for the low and high samples were
22.5% and 20.9%, respectively. Dilutional parallelism
was demonstrated. There was no significant difference
(P = 0.875) in PRA whether samples (n = 4) were
held on ice (4°C; 0.75 ng/mL/h [0.62, 0.96]) or at
room temperature (21°C; 0.68 ng/mL/h [0.59, 1.00])
or whether samples (n = 4) were analyzed immediately
(P = 0.625; 0.47 ng/mL/h [0.29, 2.15]) or frozen at
80°C for 40 days (0.48 ng/mL/h [0.29, 1.97]). The
upper limit of a reference interval generated from nor-
mal cats >9 years (mean + 2SD) was 1.52 ng/mL/h.
Measurement of Solvent-Extracted Aldosterone
Concentration
The upper limit of reference interval defined as mean
+ 2SD for PAC after solvent extraction was 106.5 pg/
mL. The mean PAC concentrations for the pooled
samples used to assess assay variability were 104 and
564 pg/ml. Intra-assay CVs (n = 6) for the samples
with low and high aldosterone concentration were 8.6
and 9.6%, respectively. Interassay CVs for samples
with low and high aldosterone concentration were
10.3% (n = 5) and 20.1% (n = 6), respectively. Dilu-
tional parallelism was demonstrated for the aldoste-
rone RIA after extraction.
Cross-Sectional Analysis of RAAS in Cats with
Variable Renal Function and Blood Pressure
Clinicopathologic data for cats grouped according
to their renal and SBP status are presented in Table 1.
The median storage time from sample collection until
analysis of PAC and PRA was 351 days (148, 706).
No significant difference in storage time was found
when cats were grouped according to SBP and renal
status (P = .785). PAC differed significantly between
groups (P < .001, Fig 1A). Cats in the Azo-HT group
demonstrated a significantly higher PAC (pg/mL,
Table 1. Clinicopathologic parameters for cats included in the cross-sectional study grouped according to blood
pressure and renal status.
Parameter
Nonazotemic
Normotensive
Nonazotemic
Hypertensive Azotemic Normotensive Azotemic Hypertensive
P
n 68 28 41 46
n
Median [25th, 75th
percentile] n
Median [25th, 75th
percentile] n
Median [25th, 75th
percentile] n
Median [25th, 75th
percentile]
Age (years) 64 12.0a [11.0, 14.0] 27 15.3b [13.8, 16.0] 40 14.5b [11.4, 17.1] 42 15.2b [13.8, 17.0] <.001
Weight (kg) 66 4.13 [3.44, 4.8] 24 3.78 [3.11, 4.55] 39 3.84 [3.10, 4.60] 39 4.00 [3.10, 4.80] .300
Body
condition (/9)
9 6.0 [4.0, 6.5] 5 4.0 [3.5, 4.5] 17 4.0 [4.0, 5.0] 9 5.0 [2.5, 5.0] –
Body
condition (/5)
18 3.5 [2.5, 4.0] 6 2.5 [1.5, 3.5] 4 2.0 [1.5, 2.5] 11 2.0 [1.5, 2.5] –
Creatinine
(mg/dL)
68 1.5a [1.3, 1.67] 28 1.6a [1.4, 1.8] 41 2.5b [2.2, 2.9] 46 2.2b [2.2, 2.9] <.001
Urea
(mmol/L)
68 9.7a [8.2, 10.7] 28 12.2b [11.2, 14.8] 41 17.9c [14.8, 20.6] 46 16.9c [13.9, 22.7] <.001
Sodium
(mEq/L)
68 151.6a [150.0, 153.0] 28 152.6ab [150.2, 154.0] 41 153.3b [151.5, 155.0] 46 153.0ab [151.0, 156.0] .006
Potassium
(mEq/L)
68 3.96 [3.60, 4.22] 28 3.82 [3.49, 4.09] 41 4.08 [3.80, 4.30] 46 3.89 [3.38, 4.21] .162
Phosphate
(mg/dL)
68 3.81a [3.34, 4.26] 28 4.30ab [3.58, 3.36] 41 4.37b [3.47, 5.76] 46 4.30b [3.73, 6.26] .007
USG 62 1.050a [1.040, 1.065] 22 1.030b [1.022, 1.042] 35 1.020c [1.017, 1.024] 37 1.018c [1.014, 1.025] <.001
UP:C 56 0.14a [0.11, 0.17] 14 0.24bc [0.19, 0.35] 26 0.15ab [0.10, 0.26] 33 0.37c [0.21, 0.84] <.001
SBP
(mmHg)
68 133.2a [114.3, 145.9] 28 200.1b [187.5, 211.0] 41 133.6a [120.8, 145.4] 46 189.1b [177.2, 216.0] <.001
n, number of cats; USG, urine specific gravity; UP:C, urine protein-to-creatinine ratio; SBP, systolic blood pressure; P, significance;
superscript letters identify groups, which differed significantly.
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n = 22, 149.8 pg/mL [103.1, 228.7]) compared with
normotensive cats with comparable renal function
(Azo-NT n = 18, 84.1 pg/mL [33.6, 137.8]) and the
Non-Azo-NT group (n = 26, 45.4 pg/mL [19.6, 65.0]).
There was no significant difference in PAC between
the Non-Azo-HT group (n = 13, 96.1 pg/mL [49.4,
106.8]) and the Non-Azo-NT group. PRA differed
significantly between cats grouped according to SBP
status (P = .0013, Fig 1B). Hypertensive cats in both
the Non-Azo-HT (n = 25, 0.22 ng/mL/h [0.09, 0.39])
and Azo-HT group (n = 44, 0.33 ng/mL/h [0.15, 0.48])
demonstrated significantly lower PRA compared with
Non-Azo-NT cats (n = 57, 0.52 ng/mL/h [0.28, 1.02]).
There was no significant difference in PRA between
Azo-HT cats and normotensive cats matched for renal
function (Azo-NT; n = 39, 0.47 ng/mL/h [0.18, 0.75]).
ARR also differed significantly between groups
(P = .0062, Fig 1C). On posthoc analysis of Azo-HT
cats (n = 20, 503.8 [298.8, 1511]) demonstrated signifi-
cantly higher ARR compared with their normotensive
counterparts (Azo-NT; n = 16, 97.8 [77.0, 496.4]), but
there was no statistically significant difference between
Non-Azo-NT (n = 22, 200.7 [106.0, 368.5]) and Non-
Azo-HT cats (n = 10, 573.7 [290.9, 1170]). No signifi-
cant correlation could be identified between plasma
potassium concentration and extracted PAC either in
the population of cats as a whole (r = 0.096,
P = .371) or in those nonazotemic cats with systemic
hypertension (r = 0.22, P = .453).
When cats were classified according to their renal
status regardless of SBP, there were no significant dif-
ferences in extracted PAC (P = .917; Fig 2A), PRA
(P = .903; Fig 2B) or ARR (P = .772; Fig 2A) among
groups. Data were also analyzed (data not shown)
including only normotensive cats, but there were no
significant differences among groups. Clinicopathologic
data for cats grouped according to plasma creatinine
concentration are presented in Table 2.
Twenty-three hypertensive cats were included in the
comparison of PRA and PAC pre- and posttreatment
with amlodipine besylate. Fourteen (60.9%) were azo-
temic before treatment. Clinicopathologic data for
these cats at the pre- and posttime points are summa-
rized in Table 3. As expected, a significant decrease in
SBP was documented with a median decrease of
50.4 mmHg [33.3, 67.6]. There was no change in
PAC (Fig 3A; P = .345, (n = 23) pre 122.8 pg/mL
[92.3, 162.4], post 108.4 [57.1, 176.5]), but a significant
increase in PRA (Fig 3B; P < .001 (n = 20), pre 0.32
ng/mL/h [0.15, 0.46], post 0.54 [0.28, 1.51]), and hence
a significant decline in ARR (P = .001 (n = 20), 440.6
[229.0, 927.1], post 148.6 [70.2, 398.1]) was docu-
mented with antihypertensive therapy.
Discussion
Results of this study show that, in nonazotemic
hypertensive cats, PRA is suppressed. PAC was signifi-
cantly increased in azotemic hypertensive cats com-
pared with normotensive cats matched for renal
function. Based on these findings, it is speculated that
A
B
C
Fig 1. Comparison of extracted aldosterone concentration,
plasma renin activity, and aldosterone-to-renin ratios in cats
grouped according to renal and blood pressure status. Compari-
son of (A) extracted aldosterone concentration (PAC), (B) plasma
renin activity (PRA), (C) aldosterone-to-renin ratio (ARR).
Horizontal bars represent the median PAC, PRA, or ARR for
each group. The dashed line represents the upper limit of the
reference interval generated from the group of normal geriatric
cats for each parameter. Non-Azo-NT; nonazotemic normoten-
sive, Non-Azo-HT; nonazotemic cats with systemic hypertension,
Azo-NT; azotemic cats normotensive, Azo-HT; azotemic cats
with systemic hypertension. *indicates statistical significance
(P < .05) was attained on posthoc analysis.
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cats may have a low renin/high PAC hypertension.
However, heterogeneity is present such that, despite
substantially larger numbers of cats, when compared
to previous studies, uncertainty still exists as to
whether this is the case for all cats.4 Decrease in PRA
may be the result of a combination of decreased renal
mass, appropriate response to increased blood pressure
or could be the consequence of age. Previous studies in
cats have documented that PRA decreases with age,
and cats in the nonazotemic normotensive group were
significantly younger than those in other groups.16
Concern is often raised regarding the diagnosis of
hypertension in cats without evidence of azotemia and
the potential for white-coat hypertension. Suppression
of PRA in these cats suggests that systemic hyperten-
sion is likely to be a genuine finding.
PRA is an important parameter for classification of
systemic hypertension in human medicine.17 Hyperten-
sive patients with low renin/high PAC can be classified
as having low-renin essential hypertension or primary
aldosteronism (PA).17 Another group of hypertensive
human patients that demonstrates suppressed renin
activity includes people of African-American descent.
Such patients are deemed to have ‘salt-sensitive’ hyper-
tension because SBP fluctuates with variable sodium
intake.18
Previous epidemiologic studies have shown that cats
with systemic hypertension demonstrate significantly
decreased plasma potassium concentrations in compari-
son with their normotensive counterparts.1 This obser-
vation may reflect a relative increase in PAC. In this
study, there was no significant difference in potassium
concentration between hypertensive and normotensive
cats with azotemia, but there was a small but significant
difference between nonazotemic hypertensive and nor-
motensive cats. However, no association could be iden-
tified between plasma potassium concentration and
PAC. Failure to demonstrate an association between
systemic hypertension and hypokalemia in this study
may reflect sample sizes. Approximately 25% of cats
had plasma potassium concentrations below the labora-
tory reference interval (3.5–5.5 mEq/L) and this was
true regardless of group. However, the results obtained
were not unexpected for cats with CKD, and no cats
had overt clinical signs of hypokalemic polymyopathy.19
Several case series have described cats with hyperald-
osteronism secondary to adrenal neoplasia.20–23 Such
cats usually demonstrate PAC substantially higher
than cats in this study, and yet not all of them will have
systemic hypertension. It therefore seems unlikely that
increased PAC is the only contributor to the develop-
ment of hypertension. In this study, increased PAC did
not appear to be driven by an increase in systemic
PRA and therefore could be primary and adrenal-
dependent. A recent study suggests that bilateral adre-
nocortical hyperplasia is an almost ubiquitous finding
in cats >9 years (97%), but there was no significant
difference in histopathologic grading between hyperten-
sive (n = 37) and normotensive cats (n = 30), support-
ing that adrenocortical hyperplasia is unlikely to be a
primary factor in feline hypertension.m A number of
A
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Fig 2. Comparison of extracted aldosterone concentration,
plasma renin activity, and aldosterone-to-renin ratios in cats
grouped according to renal status. Comparison of (A) extracted
aldosterone (PAC; P = .917; Group 1 n = 39, Group 2 n = 28,
Group 3 n = 20), (B) plasma renin activity (PRA; P = .903;
Group 1 n = 82, Group 2 n = 60, Group 3 n = 33), or (C) aldo-
sterone-to-renin ratio (ARR; P = .772; Group 1 n = 32, Group 2
n = 25, Group 3 n = 16) between groups. Horizontal bars repre-
sent the median PAC, PRA, or ARR. The dashed line represents
the upper limit of the reference interval generated from the group
of nonazotemic geriatric cats for each parameter. Open symbols
represent hypertensive cats within each group.
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other factors have been demonstrated to modulate
aldosterone production apart from angiotensin II
including extracellular potassium concentration,
adrenocorticotropic hormone, adrenomedullin, atrial
natriuretic peptide, dopamine, endogenous digitalis-like
factors (eg, ouabain) and endothelin-1, but the effect
these play in regulating aldosterone production in the
cat has not been investigated.24–29
An alternative hypothesis is that cats may demon-
strate low-renin hypertension similar to the situation
identified in hypertensive black human patients. The
pathophysiologic mechanism underlying low-renin
activity in hypertensive black patients is uncertain,
but most likely reflects differences in renal handling of
sodium among ethnic groups and a tendency for renal
retention of sodium.18 Studies suggest that hyperten-
sive black patients have significantly lower PRA than
their white counterparts and demonstrate a dispropor-
tionately increased PAC.30–32 Such patients have a
greater propensity to target organ damage and dem-
onstrate a better response to antihypertensive agents
such as calcium channel blockers and diuretics than
those targeting the RAAS.33,34 However, the role of
activation of the RAAS in salt-sensitive hypertension in
black human patients is currently debated.35 Similar to
hypertensive black patients, cats demonstrate a limited
antihypertensive response to ACEi therapy, but respond
well to calcium channel blockade.7,12 However, studies
that have investigated the effect of sodium intake on
SBP and renal function in cats have not reported an
association.36–39 Additional work is warranted to evalu-
ate salt sensitivity in naturally occurring hypertension in
cats and the role of angiotensinogen in cats with vari-
able BP and renal function.
In the cross-sectional analysis, when cats were
grouped according to renal function, although there
was no significant difference in PRA or PAC among
groups, the variance in PRA increased with severity of
azotemia. Reviewing the data from individual cats,
those cats with the highest PRA were also more mark-
edly azotemic. In these cats, it can be hypothesized
that increased PRA is an appropriate response to
dehydration and decrease renal perfusion, even if this
was not detected clinically.
Cats treated with the dihydropyridine calcium chan-
nel blocker, amlodipine besylate, showed a significant
Table 2. Clinicopathologic parameters for cats grouped according to renal status.
Parameter Group 1 Group 2 Group 3
P
n 96 62 37
n
Median [25th, 75th
percentile] n
Median [25th, 75th
percentile] n
Median [25th, 75th
percentile]
Age (years) 91 13.0a [11.0, 15.0] 58 15.0b [12.8, 17.0] 34 14.2ab [11.8, 17.0] .001
Weight (kg) 90 4.0a [3.33, 4.70] 56 4.04a [3.41, 4.82] 32 3.24b [3.00, 3.96] <.001
Creatinine (mg/dL) 96 1.5a [1.3, 1.7] 62 2.4b [2.2, 2.7] 37 3.7c [3.0, 5.27] <.001
Urea (mmol/L) 96 10.2a [8.7, 12.1] 62 16.4b [13.1, 19.0] 37 26.2c [20.7, 46.2] <.001
Sodium (mEq/L) 96 152.0a [150.0, 153.6] 62 153.0b [151.0, 154.5] 37 154.0b [151.0, 156.7] .003
Potassium (mEq/L) 96 3.90 [3.60, 4.20] 62 4.02 [3.69, 4.30] 37 3.96 [3.68, 4.28] .438
Phosphate (mg/dL) 96 3.93a [3.41, 4.57] 62 4.18a [3.49, 5.25] 37 6.71b [4.54, 10.45] <.001
USG 84 1.044a [1.033, 1.060] 50 1.020b [1.018, 1.026] 30 1.016c [1.014, 1.018] <.001
UP:C 70 0.16a [0.12, 0.20] 38 0.23b [0.13, 0.41] 31 0.45c [0.15, 0.89] <.001
SBP (mmHg) 96 142.2a [127.1, 184.0] 62 173.2b [132.8, 207.2] 37 155.6ab [134.0, 184.2] .03
Group 1: nonazotemic cats with plasma creatinine <2.0 mg/dL; Group 2: azotemic cats with plasma creatinine 2–2.8 mg/dL; Group 3:
azotemic cats with plasma creatinine ≥2.9 mg/dL; n, number of cats; USG, urine specific gravity; UP/C, urine protein-to-creatinine ratio;
SBP, systolic blood pressure; P, significance; superscript letters identify groups, which differed significantly.
Table 3. Clinicopathologic parameters for cats before and after treatment with amlodipine besylate.
Parameter n
Pretreatment
Median [25th, 75th
percentile] n
Posttreatment
Median [25th, 75th
percentile] P
SBP (mmHg) 23 193.6 [184.0, 213.6] 23 148.0 [139.2, 156.4] <.001
Creatinine (mg/dL) 23 2.2 [1.6, 2.5] 23 1.8 [1.6, 2.4] .110
Urea (mmol/L) 23 13.6 [11.7, 20.3] 23 13.7 [11.6, 18.0] .486
Sodium (mEq/L) 23 153.0 [151.0, 156.0] 23 152.0 [149.0, 153.0] .025
Potassium (mEq/L) 23 3.68 [3.46, 4.27] 23 3.57 [3.40, 3.87] .251
Phosphorus (mg/dL) 23 4.1 [3.4, 4.6] 23 4.1 [3.7, 5.1] .441
UP:C 19 0.29 [0.21, 0.43] 19 0.23 [0.15, 0.44] .454
USG 19 1.026 [1.020, 1.033] 19 1.027 [1.018, 1.036] .313
n, number of cats; USG, urine specific gravity; UP/C, urine protein-to-creatinine ratio; SBP, systolic blood pressure; P, significance
value comparing pre- and posttreatment.
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increase in PRA but no change in PAC. Previous stud-
ies in human patients receiving nifedipine and amlodi-
pine have demonstrated a significant increase in PRA
most likely because of decreased BP and sympathetic
stimulation, but effects on PAC have been conflict-
ing.40–43 The response of PRA and hence ARR to am-
lodipine treatment in cats appears appropriate and
comparable to that in humans.
There are a number of limitations to this study. The
PRA assay involves an initial incubation phase to gener-
ate Ang-1 and is dependent on angiotensinogen as a
substrate and enzymatic kinetics. Variable concentra-
tions of angiotensinogen in individual samples could
restrict generation of Ang-1 despite low, normal, or
increased PRA. Previous studies have documented cryo-
activation of prorenin to renin when human plasma is
held at temperatures <6°C.44,45 Interspecies differences
in cryoactivation of prorenin have been documented.45–47
Although sample numbers were low (n = 4), failure to
identify a difference in PRA between samples stored at
4 and 21°C supports the hypothesis that cryoactivation
of prorenin in the cat is minimal or that there is lack of
a substantial quantity of prorenin present in feline
plasma to be activated.48 The inter- and intra-assay
CVs for the PRA assay were higher than ideal in this
study and it is possible that using a smaller volume of
plasma than advocated by the manufacturer contributed
to these results. However, this was a necessity given the
residual volume of sample available from feline clinical
cases.
Plasma aldosterone concentrations have previously
been measured by either direct RIA or with solvent
extraction before RIA.4,13,16,49 In human medicine,
polar metabolites of aldosterone are known to inter-
fere with PAC quantitation and increase with
decreased renal function.15,50 No studies have evalu-
ated the influence of polar metabolites on PAC in cats.
A recent study by Syme and colleagues demonstrated
that concentrations of aldosterone excreted in feline
urine were substantially lower than reported in human
urine and that, unlike dogs and humans, cats do not
excrete glucuronidated polar metabolites of aldoste-
rone in their urine.51 As such, it is possible that accu-
mulation of polar metabolites of aldosterone is of
lesser concern in the cat, but the definitive pathway of
aldosterone metabolism and route of excretion in the
cat remain to be determined.
Substantially more PRA measurements were avail-
able than PAC measurements. In fact, missing PAC
data were available for many of the cats in this study
but had been performed using direct assessment of
PAC. Given the different methodology and reference
intervals, it was not considered appropriate to com-
bine these data. There was no significant difference in
storage times among cats grouped according to SBP
and renal status. Previous validation work from stud-
ies in humans demonstrates stability of PRA in
plasma samples frozen for up to 15 months and ste-
roid hormones for between 1 and 10 years52,53
Although it cannot be precluded that prolonged stor-
age has impacted the PRA and PAC measurements,
the distribution of this effect among groups should
remain comparable.
Cats in the Non-Azo-HT group had significantly
lower USG and higher UP:C than those in the Non-
Azo-NT group. Whether this reflects the presence of
nonazotemic kidney disease or pressure diuresis
remains uncertain. Assessment of glomerular filtra-
tion rate (GFR) could be useful to assist in clarify-
ing this, but still would not exclude the possibility of
hyperfiltration occurring in a decreased number of
nephrons. Changes in sodium intake can influence
volume status and BP, although evidence to support
this in cats is limited.38,39 In this study, the majority
of cats were eating commercially produced diets,
although the brands varied widely. Therefore, sodium
intake may have varied, but consumption of renal
diets (which are often low in sodium) was an exclu-
sion criterion.
At the visit when PRA and PAC were assessed,
total thyroxine concentrations were available for
47.4% (93/196) of cats and confirmed euthyroid sta-
tus. A recent study by Williams and colleagues dem-
onstrated that PRA and PAC significantly decreased
with treatment of hyperthyroidism in normotensive
A
B
Fig 3. (A) Line chart demonstrating change in plasma aldoste-
rone concentration before and after treatment with amlodipine
besylate. No significant change in plasma aldosterone concentra-
tion was demonstrated with amlodipine besylate therapy
(P = .584; n = 24). Median time between measurements 35 days
(25th percentile 14, 75th percentile 56). (B) Line chart demon-
strating change in plasma renin activity before and after treat-
ment with amlodipine besylate. A significant increase (P < .001;
n = 20) in plasma renin activity was demonstrated with amlodi-
pine besylate therapy. Median time between measurements
28 days (25th percentile 14, 75th percentile 56).
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cats, but that PAC did not change significantly in
those cats that became hypertensive with treatment.54
Occult hyperthyroidism in the current cohort of cats
could therefore have impacted the PRA and PAC
results. Whenever possible, urine samples were
obtained from cats. However, because of financial
constraints, it was not routine for urine culture to be
performed unless an active sediment, bacteriuria, or
both were evident on urinalysis. It is possible that
renal scarring because of recurrent episodes of chronic
pyelonephritis influenced the kidney’s ability to
respond to the RAAS. Within the limits of this study
protocol, occult urinary tract infections or episodes of
pyelonephritis may not have been identified. Finally,
cats did not undergo routine diagnostic imaging and it
is therefore possible that adrenal mass lesions may
have gone undetected. The study by Keele and col-
leagues examining adrenal gland histopathology from
cats >9 years reported a prevalence of only 3% (2/67)
for adrenal adenomas.m Given that this study was per-
formed using a tissue archive from the authors’ group,
it can be anticipated that the prevalence would be
similar.
In conclusion, on a population basis, azotemic
hypertensive cats showed significantly increased PAC
and ARR independent of PRA. Nonazotemic hyper-
tensive cats showed significantly suppressed PRA.
However, there was substantial overlap among all
groups of cats such that, despite larger numbers of
cats in this study, it remains difficult to fully establish
the role of the RAAS that is playing in the genesis of
hypertension in cats. Additional work is required to
establish whether suppressed PRA and relative
increase in PAC reflects autonomous aldosterone
production or if the cat represents a potential model
for low-renin hypertension identified in hypertensive
black humans.
Footnotes
a Parks Electronic Doppler Model 811B; Perimed UK, Bury St
Edmunds, UK
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d Istin, Pfizer, Maidenhead, UK
e GammaCoat Plasma Renin Activity, Diasorin, MN
f Coat-A-Count, Diagnostic Products Corporation, CA
g Sigma-Aldrich Company Ltd, Poole, Dorset, UK
h Amersham Pharmacia Biotech UK, Buckinghamshire, UK
i Beckman Gold, Packard Bioscience, Groningen, The Nether-
lands
j Packard Tri-Carb 4530, Groningen, The Netherlands
k IBM SPSS Statistics 19, IBM United Kingdom Ltd,
Portsmouth, Hampshire, UK
l GraphPad Prism version 5, La Jolla, CA
m Keele SJ, Smith K, Elliott J, et al. Adrenocortical morphology
in cats with chronic kidney disease (CKD) and systemic hyper-
tension. J Vet Intern Med 2009; 23: 1328 (abstract)
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